Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer

Journal of Digestive Diseases

Volumn 10, Issue 2, 2009, Pages 118-123

  Cui, Yue Hong ^a   Liu, Tian Shu ^a   Zhuang, Rong Yuan ^a   Gao, Hen Jun ^b   Li, Hong ^a  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Outdo Biotech Co   (China)

Author keywords

5 fluorouracil; Chemosensitivity; Polymorphism; Thymidylate synthase

Indexed keywords

FLUOROURACIL; THYMIDYLATE SYNTHASE;

5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; BASE PAIRING; CHEMOSENSITIVITY; CHINESE; COLORECTAL CANCER; DISEASE COURSE; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; STOMACH CANCER;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; THYMIDYLATE SYNTHASE;

EID: 65449117932     PISSN: 17512972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2009.00373.x     Document Type: Article

References (12)

1. Toriumi F, Kubota T, Saikawa Y et al. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Anticancer Res 2004; 24: 2455-63.
2. Kaneko M, Kawakami K, Oyama K et al. The association of expression and gene polymorphism of the thymidylate synthase gene with 5-fluoro-5′-deoxyuridine sensitivity in gastric cancer cell lines. Gan Kagaku Ryoho 2004; 31: 1347-50 (in Japanese).
3. Cui Yajing Zhang Jianhui. Relationship of polymorphism of thymidylate synthase and tumor. Section Genet Foreign Med Sci 2004; 27: 349-53 (in Chinese).
4. Lacopetta B, Grieu F, Joseph D et al. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001; 85: 827-30.
5. Marsh S, Mckay JA, Cassidy J et al. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001; 19: 383-6.
6. Tsuji T, Hidaka S, Sawai T et al. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res 2003; 9: 3700-4.
7. Hori T, Takahashi E, Ayusawa D et al. Regional assignment of the human thymidylate synthase (TS) gene to chromosome band 18p11.32 by non-isotopic in situ hybridization. Human Genet 1990; 85: 576-80.
8. Yu K, Wang W. Polymorphisms of the thymidylate synthase gene promoter in primary colon cancer and its relationship with clinical pathological parameters. Chin J Digestion 2006; 26: 35-7.
9. Yu K-h, Zhang X-b. Polymorphism of the thymidylate synthase gene promoter in bladder transitional cell carcinoma and its relationship with invasiveness. J Chin Physician 2006; 8: 732-4. [in Chinese].
10. Burns MA, Johnson BN, Brahmasandra SN et al. An integrated nanoliter DNA analysis device. Science 1998; 282: 484-7.
11. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-37.
12. Ichikawa W. Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients in terms of the 5-fluorouracil metabolic way. Gastric Cancer 2006; 9: 145-55.